Multitude Therapeutics’ AMT-676 Receives Breakthrough Therapy Designation from China’s CDE
On June 26, 2026, the Center for Drug Evaluation (…
U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253
On July 24, 2026, the U.S. Food and Drug Administr…
Multitude Therapeutics Announces Encouraging Interim Phase I Results from Ongoing First-in-Human Study Evaluating its CDH17-directed Antibody-Drug-Conjugate, AMT-676, in patients with advanced CRC at the 2026 ESMO GI Cancer Congress
AMT-676 is a potential first-in-class CDH17-direct…
Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
Download Full Poster (PDF) 112P – Phase I st…
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation
December 17, 2025, according to the official websi…